Table 6.
Laboratory parameters in critical patients with HFRS during the acute stage
| Variables |
Survivors (n = 46) |
Non-survivors (n = 29) |
P value a | ||
|---|---|---|---|---|---|
| Mean ± SD | n b | Mean ± SD | n b | ||
| Maximum WBC, 109 cells/L |
34.43 ± 16.02c |
39 |
47.95 ± 21.78c |
26 |
.005 |
| Nadir PLT, 109 cells/L |
12.18 ± 11.16d |
39 |
14.35 ± 10.28d |
26 |
.432 |
| Maximum HGB, g/L |
171.00 ± 24.11c |
39 |
166.92 ± 26.42c |
25 |
.162 |
| Maximum ALT, u/L |
170.11 ± 210.92c |
44 |
502.91 ± 859.69c |
29 |
.213 |
| Nadir serum ALB, g/L |
24.53 ± 4.92d |
44 |
22.45 ± 5.20d |
29 |
.088 |
| Maximum BUN, mmol/L |
31.13 ± 8.58c |
44 |
26.34 ± 12.77c |
29 |
.084 |
| Maximum Scr, μmol/L |
778.46 ± 220.86c |
44 |
479.66 ± 254.29c |
29 |
<.001 |
| Maximum glucose, mmol/L |
13.32 ± 6.00c |
43 |
15.34 ± 8.22c |
28 |
.235 |
| Longest PT, sec |
15.20 ± 3.44c |
45 |
20.53 ± 9.15c |
28 |
.006 |
| Longest APTT, sec |
45.96 ± 14.79c |
45 |
59.52 ± 19.94c |
28 |
.003 |
| Longest TT, sec |
23.86 ± 6.24c |
45 |
25.32 ± 6.72c |
28 |
.282 |
| Minimum Fib, g/L | 1.84 ± 0.82d | 44 | 1.46 ± 0.84d | 29 | .056 |
Reference values: WBC (3.2-9.7) × 109/L; PLT (100–300) × 109/L; HGB (120–160) g/L (male), (110–150) g/L (female); ALT (4–44) U/L; serum ALB (35–55) g/L; serum BUN (2.86-8.20) mmol/L; serum Cr (53–97) μmol/L (male), (35–71) μmol/L (female); glucose (3.89-6.11) mmol/L; PT (8.8-13.8) sec; APTT (25.1-36.5) sec; TT (10.3-16.6) sec, Fib (2.38-4.98) g/L.
Abbreviations: WBC, white blood cells; PLT, platelet; HGB, hemoglobin; ALT, alanine aminotransferase; ALB, albumin; BUN, blood urea nitrogen; Scr, serum creatinine; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; Fib, fibrinogen.
aSurvivors vs. non-survivors.
bSome critical patients had passed through the acute stage on admission, and therefore, no laboratory data were available.
cHigher or longer than the reference value, P < .001.
dLower than the reference value, P < .001.